drugset / Trial / NCT06331312
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Timeline
- Start
- 2024-06-28
- Primary completion
- 2028-05-08
- Completion
- 2028-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |